Engineering Lineage Potency and Plasticity of Stem Cells using Epigenetic Molecules
Open Access
- 2 November 2018
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 16289
Abstract
Stem cells are considered as a multipotent regenerative source for diseased and dysfunctional tissues. Despite the promise of stem cells, the inherent capacity of stem cells to convert to tissue-specific lineages can present a major challenge to the use of stem cells for regenerative medicine. We hypothesized that epigenetic regulating molecules can modulate the stem cell’s developmental program, and thus potentially overcome the limited lineage differentiation that human stem cells exhibit based on the source and processing of stem cells. In this study, we screened a library of 84 small molecule pharmacological agents indicated in nucleosomal modification and identified a sub-set of specific molecules that influenced osteogenesis in human mesenchymal stem cells (hMSCs) while maintaining cell viability in-vitro. Pre-treatment with five candidate hits, Gemcitabine, Decitabine, I-CBP112, Chidamide, and SIRT1/2 inhibitor IV, maximally enhanced osteogenesis in-vitro. In contrast, five distinct molecules, 4-Iodo-SAHA, Scriptaid, AGK2, CI-amidine and Delphidine Chloride maximally inhibited osteogenesis. We then tested the role of these molecules on hMSCs derived from aged human donors and report that small epigenetic molecules, namely Gemcitabine and Chidamide, can significantly promote osteogenic differentiation by 5.9- and 2.3-fold, respectively. Taken together, this study demonstrates new applications of identified small molecule drugs for sensitively regulating the lineage plasticity fates of bone-marrow derived mesenchymal stem cells through modulating the epigenetic profile of the cells.Keywords
Funding Information
- National Institute of Biomedical Imaging and Bioengineering (EB001046, EB001046, T32EB005583, EB001046)
This publication has 73 references indexed in Scilit:
- The class I-specific HDAC inhibitor MS-275 modulates the differentiation potential of mouse embryonic stem cellsBiology Open, 2013
- Epigenetic Dysregulation in Mesenchymal Stem Cell Aging and Spontaneous DifferentiationPLOS ONE, 2011
- Association of adipogenic genes with SC-35 domains during porcine adipogenesisChromosome Research, 2010
- Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cellsBiochemical and Biophysical Research Communications, 2010
- Therapeutic potential of adult bone marrow‐derived mesenchymal stem cells in diseases of the skeletonJournal of Cellular Biochemistry, 2010
- Cellular Heterogeneity: Do Differences Make a Difference?Cell, 2010
- Epigenetic characterization of hematopoietic stem cell differentiation using miniChIP and bisulfite sequencing analysisProceedings of the National Academy of Sciences, 2007
- High-Resolution Profiling of Histone Methylations in the Human GenomeCell, 2007
- Inhibition of Histone Acetylation as a Tool in Bone Tissue EngineeringTissue Engineering, 2006
- The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1British Journal of Cancer, 2002